{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:34:13Z","timestamp":1790696053349,"version":"4.1.0"},"reference-count":204,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R03CA259865"],"award-info":[{"award-number":["R03CA259865"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA262873"],"award-info":[{"award-number":["R01CA262873"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R21CA227926"],"award-info":[{"award-number":["R21CA227926"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex&apos;s Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006261","name":"Ohio Development Services Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.annonc.2022.03.011","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:43:22Z","timestamp":1648039402000},"page":"578-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities"],"prefix":"10.1016","volume":"33","author":[{"given":"A.S.","family":"Venkataramany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Schieffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.R.","family":"Mardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2022.03.011_bib1","series-title":"Global Cancer Facts & Figures","year":"2020"},{"issue":"25","key":"10.1016\/j.annonc.2022.03.011_bib2","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMsr1804754","article-title":"The major causes of death in children and adolescents in the United States","volume":"379","author":"Cunningham","year":"2018","journal-title":"N\u00a0Eng J Med"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib3","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S1470-2045(13)70010-X","article-title":"Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries","volume":"14","author":"Pritchard-Jones","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6432","key":"10.1016\/j.annonc.2022.03.011_bib4","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1126\/science.aaw4892","article-title":"Science and health for all children with cancer","volume":"363","author":"Lam","year":"2019","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41591-019-0383-9","article-title":"Developmental origins and emerging therapeutic opportunities for childhood cancer","volume":"25","author":"Filbin","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms4630","article-title":"The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes","volume":"5","author":"Huether","year":"2014","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10555-019-09836-y","article-title":"Compare and contrast: pediatric cancer versus adult malignancies","volume":"38","author":"Kattner","year":"2019","journal-title":"Cancer Metastasis Rev"},{"issue":"7696","key":"10.1016\/j.annonc.2022.03.011_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"issue":"7696","key":"10.1016\/j.annonc.2022.03.011_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.annonc.2022.03.011_bib10","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1158\/1078-0432.CCR-10-0438","article-title":"A\u00a0distinct spectrum of copy number aberrations in pediatric high-grade gliomas","volume":"16","author":"Bax","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"7249","key":"10.1016\/j.annonc.2022.03.011_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nature08035","article-title":"Copy number variation at 1q21. 1 associated with neuroblastoma","volume":"459","author":"Diskin","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cge.13600","article-title":"Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition","volume":"96","author":"Gambale","year":"2019","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.011_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.2287","article-title":"The pediatric cancer genome project","volume":"44","author":"Downing","year":"2012","journal-title":"Nat Genet"},{"issue":"2083","key":"10.1016\/j.annonc.2022.03.011_bib14","doi-asserted-by":"crossref","first-page":"590033","DOI":"10.3389\/fonc.2020.590033","article-title":"Genetic predisposition to solid pediatric cancers","volume":"10","author":"Capasso","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib15","first-page":"1","article-title":"Alternative splicing and cancer: a systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"15-16","key":"10.1016\/j.annonc.2022.03.011_bib16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1101\/gad.338962.120","article-title":"Alternative splicing and cancer: insights, opportunities, and challenges from an expanding view of the transcriptome","volume":"34","author":"Cherry","year":"2020","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12967-019-2029-6","article-title":"Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas","volume":"17","author":"Yang","year":"2019","journal-title":"J\u00a0Transl Med"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1159\/000492094","article-title":"Prognostic signature of alternative splicing events in bladder urothelial carcinoma based on Spliceseq data from 317 cases","volume":"48","author":"He","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tig.2018.10.002","article-title":"RNA splicing and disease: animal models to therapies","volume":"35","author":"Montes","year":"2019","journal-title":"Trends Genet"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib20","doi-asserted-by":"crossref","first-page":"e1476","DOI":"10.1002\/wrna.1476","article-title":"Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics","volume":"9","author":"Urbanski","year":"2018","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.annonc.2022.03.011_bib21","series-title":"Cancer Facts & Figures\u00a02022","year":"2022"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.2625","article-title":"Prognostic significance of alterations in KRAS isoforms KRAS-4A\/4B and KRAS mutations in colorectal carcinoma","volume":"219","author":"Abubaker","year":"2009","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ijc.31809","article-title":"Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer","volume":"144","author":"Eilertsen","year":"2019","journal-title":"Int J Cancer"},{"issue":"29","key":"10.1016\/j.annonc.2022.03.011_bib24","doi-asserted-by":"crossref","first-page":"20578","DOI":"10.18632\/oncotarget.25016","article-title":"Role of epigenetic factors in the selection of the alternative splicing isoforms of human KRAS in colorectal cancer cell lines","volume":"9","author":"Riffo-Campos","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.yexcr.2005.10.004","article-title":"The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice","volume":"312","author":"Plowman","year":"2006","journal-title":"Exp Cell Res"},{"issue":"24","key":"10.1016\/j.annonc.2022.03.011_bib27","doi-asserted-by":"crossref","first-page":"17164","DOI":"10.1074\/jbc.274.24.17164","article-title":"Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility","volume":"274","author":"Voice","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib28","first-page":"259","article-title":"K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer","volume":"25","author":"Plowman","year":"2006","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.011_bib29","first-page":"920","article-title":"Aberrant alternative splicing in breast cancer","volume":"11","author":"Yang","year":"2019","journal-title":"J\u00a0Mol Cell Biol"},{"issue":"9","key":"10.1016\/j.annonc.2022.03.011_bib30","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","article-title":"The BRCA1-\u039411q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res"},{"issue":"1-2","key":"10.1016\/j.annonc.2022.03.011_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2008.11.001","article-title":"The role of KLF6 and its splice variants in cancer therapy","volume":"12","author":"DiFeo","year":"2009","journal-title":"Drug Resist Updat"},{"issue":"169","key":"10.1016\/j.annonc.2022.03.011_bib32","doi-asserted-by":"crossref","first-page":"169ra12","DOI":"10.1126\/scitranslmed.3004688","article-title":"KLF6-SV1 drives breast cancer metastasis and is associated with poor survival","volume":"5","author":"Hatami","year":"2013","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.annonc.2022.03.011_bib33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","article-title":"Alternative splicing in prostate cancer","volume":"15","author":"Paschalis","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.annonc.2022.03.011_bib35","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-17-0017","article-title":"Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance","volume":"23","author":"Kohli","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.03.011_bib36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.phrs.2016.10.001","article-title":"Androgen receptor variation affects prostate cancer progression and drug resistance","volume":"114","author":"McCrea","year":"2016","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3233\/CBM-150505","article-title":"Quantification of insulin receptor mRNA splice variants as a diagnostic tumor marker in breast cancer","volume":"15","author":"Aljada","year":"2015","journal-title":"Cancer Biomark"},{"issue":"12","key":"10.1016\/j.annonc.2022.03.011_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050953","article-title":"Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and-2 are differentially expressed in prostate cancer","volume":"7","author":"Heni","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.011_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026177","article-title":"Altered expression of insulin receptor isoforms in breast cancer","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2407-14-131","article-title":"Increased IR-A\/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma","volume":"14","author":"Jiang","year":"2014","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.011_bib41","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1158\/1055-9965.EPI-14-0177","article-title":"Reduced insulin-like growth factor I receptor and altered insulin receptor isoform mRNAs in normal mucosa predict colorectal adenoma risk","volume":"23","author":"Santoro","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib42","doi-asserted-by":"crossref","first-page":"31222","DOI":"10.1038\/srep31222","article-title":"Insulin receptor alternative splicing is regulated by insulin signaling and modulates beta cell survival","volume":"6","author":"Malakar","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2022.03.011_bib43","first-page":"93","article-title":"The insulin receptor: a new target for cancer therapy","volume":"2","author":"Belfiore","year":"2011","journal-title":"Front Endocrinol"},{"issue":"11","key":"10.1016\/j.annonc.2022.03.011_bib44","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.3390\/ijms19113615","article-title":"Insulin receptor isoforms in cancer","volume":"19","author":"Vella","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.annonc.2022.03.011_bib45","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/1541-7786.MCR-15-0279","article-title":"Intrinsic resistance to cixutumumab is conferred by distinct isoforms of the insulin receptor","volume":"13","author":"Forest","year":"2015","journal-title":"Mol Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/er.2017-00073","article-title":"Insulin receptor isoforms in physiology and disease: an updated view","volume":"38","author":"Belfiore","year":"2017","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.annonc.2022.03.011_bib47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1541-7786.MCR-14-0131","article-title":"Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer","volume":"12","author":"Das","year":"2014","journal-title":"Mol Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.011_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046539","article-title":"Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma","volume":"7","author":"Gout","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nsmb1209","article-title":"The gene encoding the splicing factor SF2\/ASF is a proto-oncogene","volume":"14","author":"Karni","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"15-16","key":"10.1016\/j.annonc.2022.03.011_bib50","doi-asserted-by":"crossref","first-page":"2000044","DOI":"10.1002\/pmic.202000044","article-title":"Over-expression of RNA processing, heat shock, and DNA repair proteins in breast tumor compared to normal tissue","volume":"20","author":"Yen","year":"2020","journal-title":"Proteomics"},{"issue":"7279","key":"10.1016\/j.annonc.2022.03.011_bib51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nature08697","article-title":"HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer","volume":"463","author":"David","year":"2010","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.annonc.2022.03.011_bib52","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"issue":"11-12","key":"10.1016\/j.annonc.2022.03.011_bib53","doi-asserted-by":"crossref","first-page":"194388","DOI":"10.1016\/j.bbagrm.2019.05.006","article-title":"Alternative splicing in lung cancer","volume":"1862","author":"Coomer","year":"2019","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","article-title":"Hereditary cancer predisposition syndromes","volume":"23","author":"Garber","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib55","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajmg.a.38142","article-title":"Childhood cancer predisposition syndromes\u2014a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology","volume":"173","author":"Ripperger","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10689-004-7993-0","article-title":"Lynch syndrome genes","volume":"4","author":"Peltom\u00e4ki","year":"2005","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10689-011-9427-0","article-title":"Mutation deep within an intron of MSH2 causes Lynch syndrome","volume":"10","author":"Clendenning","year":"2011","journal-title":"Fam Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10689-009-9280-6","article-title":"Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay","volume":"8","author":"Naruse","year":"2009","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005756","article-title":"Exonic splicing mutations are more prevalent than currently estimated and can be predicted by using in silico tools","volume":"12","author":"Soukarieh","year":"2016","journal-title":"PLoS Genet"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007231","article-title":"Hereditary cancer genes are highly susceptible to splicing mutations","volume":"14","author":"Rhine","year":"2018","journal-title":"PLoS Genet"},{"issue":"18","key":"10.1016\/j.annonc.2022.03.011_bib61","first-page":"5358","article-title":"A\u00a0cancer family syndrome in twenty-four kindreds","volume":"48","author":"Li","year":"1988","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.011_bib62","first-page":"1365","article-title":"Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome","volume":"43","author":"Li","year":"1969","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib63","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7326\/0003-4819-71-4-747","article-title":"Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome?","volume":"71","author":"Li","year":"1969","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1997.328","article-title":"Li-Fraumeni syndrome \u2013 a molecular and clinical review","volume":"76","author":"Varley","year":"1997","journal-title":"Br J Cancer"},{"issue":"37","key":"10.1016\/j.annonc.2022.03.011_bib65","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1038\/sj.onc.1203758","article-title":"Novel p53 splice site mutations in three families with Li-Fraumeni syndrome","volume":"19","author":"Verselis","year":"2000","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib66","first-page":"608","article-title":"Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome","volume":"56","author":"Frebourg","year":"1995","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.011_bib67","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mc.20537","article-title":"Li\u2013Fraumeni and Li\u2013Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements","volume":"48","author":"Kouidou","year":"2009","journal-title":"Mol Carcinog"},{"issue":"25","key":"10.1016\/j.annonc.2022.03.011_bib68","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1201878","article-title":"Genetic and functional studies of a germline TP53 splicing mutation in a Li\u2013Fraumeni-like family","volume":"16","author":"Varley","year":"1998","journal-title":"Oncogene"},{"issue":"43","key":"10.1016\/j.annonc.2022.03.011_bib69","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/sj.onc.1209877","article-title":"The CHEK2 gene and inherited breast cancer susceptibility","volume":"25","author":"Nevanlinna","year":"2006","journal-title":"Oncogene"},{"issue":"52","key":"10.1016\/j.annonc.2022.03.011_bib70","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1038\/sj.onc.1207928","article-title":"Alternative splicing and mutation status of CHEK2 in stage III breast cancer","volume":"23","author":"Staalesen","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1593\/neo.111574","article-title":"Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma","volume":"14","author":"Yang","year":"2012","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1086\/346094","article-title":"Mutations in CHEK2 associated with prostate cancer risk","volume":"72","author":"Dong","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.011_bib73","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky1231","article-title":"Aberrant splicing in B-cell acute lymphoblastic leukemia","volume":"47","author":"Black","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"10.1016\/j.annonc.2022.03.011_bib75","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1038\/onc.2012.288","article-title":"Downregulation of splicing factor SRSF3 induces p53\u03b2, an alternatively spliced isoform of p53 that promotes cellular senescence","volume":"32","author":"Tang","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib77","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","article-title":"Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia","volume":"45","author":"Meyer","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib78","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2006.01.020","article-title":"p53 ubiquitination: Mdm2 and beyond","volume":"21","author":"Brooks","year":"2006","journal-title":"Mol Cell"},{"issue":"9","key":"10.1016\/j.annonc.2022.03.011_bib80","doi-asserted-by":"crossref","DOI":"10.1593\/neo.13286","article-title":"Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma","volume":"15","author":"Jacob","year":"2013","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/onc.2017.282","article-title":"A\u00a0novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in\u00a0vivo","volume":"37","author":"Comiskey","year":"2018","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.annonc.2022.03.011_bib82","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1093\/nar\/gkv223","article-title":"Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage","volume":"43","author":"Comiskey","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/1541-7786.29.2.1","article-title":"MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides","volume":"2","author":"Bartel","year":"2004","journal-title":"Mol Cancer Res"},{"issue":"14","key":"10.1016\/j.annonc.2022.03.011_bib84","first-page":"1001","article-title":"The MDM2-p53 interaction","volume":"1","author":"Moll","year":"2003","journal-title":"Mol Cancer Res"},{"issue":"8","key":"10.1016\/j.annonc.2022.03.011_bib85","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/nm0896-912","article-title":"Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer","volume":"2","author":"Sigalas","year":"1996","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.011_bib86","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1158\/0008-5472.CAN-08-2645","article-title":"Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma","volume":"69","author":"Avnet","year":"2009","journal-title":"Cancer Res"},{"issue":"54","key":"10.1016\/j.annonc.2022.03.011_bib87","doi-asserted-by":"crossref","first-page":"8240","DOI":"10.1038\/sj.onc.1206058","article-title":"In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A","volume":"21","author":"Sciacca","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-021-00245-5","article-title":"Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma","volume":"6","author":"Khurshid","year":"2022","journal-title":"NPJ Precision Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2022.03.011_bib89","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing sarcoma: current management and future approaches through collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2022.03.011_bib90","doi-asserted-by":"crossref","first-page":"E1307","DOI":"10.1073\/pnas.1500536112","article-title":"Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing","volume":"112","author":"Selvanathan","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib91","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/cells9020328","article-title":"Poison-exon inclusion in DHX9 reduces its expression and sensitizes Ewing sarcoma cells to chemotherapeutic treatment","volume":"9","author":"Palombo","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056408","article-title":"Genomic EWS-FLI1 fusion sequences in Ewing sarcoma resemble breakpoint characteristics of immature lymphoid malignancies","volume":"8","author":"Berger","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib93","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.celrep.2015.12.063","article-title":"Functional genomic screening reveals splicing of the EWS-FLI1 fusion transcript as a vulnerability in Ewing Sarcoma","volume":"14","author":"Grohar","year":"2016","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.annonc.2022.03.011_bib94","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1261\/rna.072454.119","article-title":"HNRNPH1-dependent splicing of a fusion oncogene reveals a targetable RNA G-quadruplex interaction","volume":"25","author":"Neckles","year":"2019","journal-title":"RNA"},{"issue":"27","key":"10.1016\/j.annonc.2022.03.011_bib95","doi-asserted-by":"crossref","first-page":"42716","DOI":"10.18632\/oncotarget.8446","article-title":"The biology of DHX9 and its potential as a therapeutic target","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2022.03.011_bib96","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fgene.2018.00170","article-title":"RNA-sequencing of primary retinoblastoma tumors provides new insights and challenges into tumor development","volume":"9","author":"Elchuri","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.annonc.2022.03.011_bib97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2019.00221","article-title":"Non-coding and coding transcriptional profiles are significantly altered in pediatric retinoblastoma tumors","volume":"9","author":"Rajasekaran","year":"2019","journal-title":"Front Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2022.03.011_bib98","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM198912213212501","article-title":"Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling","volume":"321","author":"Yandell","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.03.011_bib99","series-title":"Principles of Clinical Cancer Genetics","first-page":"163","article-title":"Pediatric malignancies: retinoblastoma and Wilms\u2019 tumor","author":"Sweetser","year":"2010"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib100","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3934\/mbe.2021017","article-title":"Identification of driver genes with aberrantly alternative splicing events in pediatric patients with retinoblastoma","volume":"18","author":"Yang","year":"2020","journal-title":"Math Biosci Eng"},{"issue":"8","key":"10.1016\/j.annonc.2022.03.011_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042739","article-title":"Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma","volume":"7","author":"McEvoy","year":"2012","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.annonc.2022.03.011_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028579","article-title":"Disabled-1 alternative splicing in human fetal retina and neural tumors","volume":"6","author":"Katyal","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.39.5.e21","article-title":"AT to C mutation in the polypyrimidine tract of the exon 9 splicing site of the RB1 gene responsible for low penetrance hereditary retinoblastoma","volume":"39","author":"Lefevre","year":"2002","journal-title":"J\u00a0Med Genet"},{"issue":"5-6","key":"10.1016\/j.annonc.2022.03.011_bib104","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s004390050551","article-title":"A\u00a0splicing mutation in RB1 in low penetrance retinoblastoma","volume":"100","author":"Schubert","year":"1997","journal-title":"Hum Genet"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhg.2015.173","article-title":"Familial retinoblastoma due to intronic LINE-1 insertion causes aberrant and noncanonical mRNA splicing of the RB1 gene","volume":"61","author":"Rodr\u00edguez-Mart\u00edn","year":"2016","journal-title":"J\u00a0Hum Genet"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.011_bib106","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/jmedgenet-2014-102264","article-title":"RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients","volume":"51","author":"Dommering","year":"2014","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib107","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/humu.20664","article-title":"Patterns of missplicing caused by RB1 gene mutations in patients with retinoblastoma and association with phenotypic expression","volume":"29","author":"Zhang","year":"2008","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib108","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1086\/341284","article-title":"A\u00a0parent-of-origin effect in two families with retinoblastoma is associated with a distinct splice mutation in the RB1 gene","volume":"71","author":"Klutz","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/345651","article-title":"Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma","volume":"72","author":"Richter","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.annonc.2022.03.011_bib110","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7150\/ijbs.6.806","article-title":"SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance","volume":"6","author":"Jia","year":"2010","journal-title":"Int J Biol Sci"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib111","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/nar\/gkv1500","article-title":"A\u00a0genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells","volume":"44","author":"Ajiro","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib112","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1261\/rna.068619.118","article-title":"Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation","volume":"25","author":"Jia","year":"2019","journal-title":"RNA"},{"issue":"4680","key":"10.1016\/j.annonc.2022.03.011_bib113","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1126\/science.6505694","article-title":"Activated expression of the N-myc gene in human neuroblastomas and related tumors","volume":"226","author":"Kohl","year":"1984","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib114","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2015.11.045","article-title":"MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma","volume":"371","author":"Zhang","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.annonc.2022.03.011_bib115","doi-asserted-by":"crossref","first-page":"242513","DOI":"10.1155\/2013\/242513","article-title":"PKM2, a central point of regulation in cancer metabolism","volume":"2013","author":"Wong","year":"2013","journal-title":"Int J Cell Biol"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib116","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0092-8674(01)00453-6","article-title":"Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation","volume":"106","author":"Hammes","year":"2001","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.011_bib117","first-page":"3957","article-title":"WT1 splicing alterations in Wilms\u2019 tumors","volume":"6","author":"Baudry","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib118","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrc3002","article-title":"Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene","volume":"11","author":"Huff","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib119","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/excr.2000.5131","article-title":"Wilms tumor and the WT1 gene","volume":"264","author":"Lee","year":"2001","journal-title":"Exp Cell Res"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ejh.13010","article-title":"DNA and RNA binding by the Wilms' tumour gene 1 (WT 1) protein+ KTS and\u2212 KTS isoforms\u2014From initial observations to recent global genomic analyses","volume":"100","author":"Ullmark","year":"2018","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib121","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/cells9030760","article-title":"Transcription factors in cancer: when alternative splicing determines opposite cell fates","volume":"9","author":"Belluti","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib122","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jmb.2007.07.017","article-title":"Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA","volume":"372","author":"Stoll","year":"2007","journal-title":"J\u00a0Mol Biol"},{"issue":"22","key":"10.1016\/j.annonc.2022.03.011_bib123","doi-asserted-by":"crossref","first-page":"11932","DOI":"10.1073\/pnas.97.22.11932","article-title":"Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein","volume":"97","author":"Laity","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib124","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0092-8674(95)90392-5","article-title":"Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing","volume":"81","author":"Larsson","year":"1995","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib125","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.tranon.2014.07.008","article-title":"The Wilms' tumor gene WT1\u2212 17AA\/\u2212 KTS splice variant increases tumorigenic activity through up-regulation of vascular endothelial growth factor in an in\u00a0vivo ovarian cancer model","volume":"7","author":"Yamanouchi","year":"2014","journal-title":"Transl Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib126","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/ng1297-467","article-title":"Donor splice-site mutations in WT1 are responsible for Frasier syndrome","volume":"17","author":"Barbaux","year":"1997","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib127","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/hmg\/7.4.709","article-title":"Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1+\/\u2212 KTS splice isoforms","volume":"7","author":"Klamt","year":"1998","journal-title":"Hum Mol Genet"},{"issue":"40","key":"10.1016\/j.annonc.2022.03.011_bib128","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1021\/acs.biochem.0c00602","article-title":"RNA binding by the KTS splice variants of Wilms\u2019 tumor suppressor protein WT1","volume":"59","author":"Nishikawa","year":"2020","journal-title":"Biochemistry"},{"issue":"D1","key":"10.1016\/j.annonc.2022.03.011_bib129","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.annonc.2022.03.011_bib130","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum Mutat"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib131","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10875-016-0281-6","article-title":"Dominant splice site mutations in PIK3R1 cause hyper IgM syndrome, lymphadenopathy and short stature","volume":"36","author":"Petrovski","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"issue":"13","key":"10.1016\/j.annonc.2022.03.011_bib132","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"51","key":"10.1016\/j.annonc.2022.03.011_bib133","doi-asserted-by":"crossref","first-page":"E5564","DOI":"10.1073\/pnas.1419260111","article-title":"Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma","volume":"111","author":"Perry","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib134","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12311-017-0899-9","article-title":"Epigenetic drivers in pediatric medulloblastoma","volume":"17","author":"Roussel","year":"2018","journal-title":"Cerebellum"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"10.1016\/j.annonc.2022.03.011_bib136","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"7663","key":"10.1016\/j.annonc.2022.03.011_bib137","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature22973","article-title":"The whole-genome landscape of medulloblastoma subtypes","volume":"547","author":"Northcott","year":"2017","journal-title":"Nature"},{"issue":"7409","key":"10.1016\/j.annonc.2022.03.011_bib138","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature11213","article-title":"Novel mutations target distinct subgroups of medulloblastoma","volume":"488","author":"Robinson","year":"2012","journal-title":"Nature"},{"issue":"W1","key":"10.1016\/j.annonc.2022.03.011_bib139","doi-asserted-by":"crossref","first-page":"W597","DOI":"10.1093\/nar\/gks400","article-title":"ExPASy: SIB bioinformatics resource portal","volume":"40","author":"Artimo","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib140","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1086\/302809","article-title":"Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain","volume":"66","author":"Fahsold","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib141","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.117.10296","article-title":"Whole exome sequencing reveals a monogenic cause of disease in \u224843% of 35 families with midaortic syndrome","volume":"71","author":"Warejko","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.011_bib142","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/ajmg.a.38212","article-title":"Moyamoya syndrome in children with neurofibromatosis type 1: Italian\u2013French experience","volume":"173","author":"Santoro","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.011_bib143","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/1479-7364-5-6-623","article-title":"Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis","volume":"5","author":"Laycock-van Spyk","year":"2011","journal-title":"Hum Genomics"},{"issue":"11","key":"10.1016\/j.annonc.2022.03.011_bib144","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41577-019-0195-7","article-title":"Alternative mRNA splicing in cancer immunotherapy","volume":"19","author":"Frankiw","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib146","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.celrep.2018.03.052","article-title":"Systematic analysis of splice-site-creating mutations in cancer","volume":"23","author":"Jayasinghe","year":"2018","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.annonc.2022.03.011_bib147","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2022.03.011_bib148","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nbt.4239","article-title":"Intron retention is a source of neoepitopes in cancer","volume":"36","author":"Smart","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"470","key":"10.1016\/j.annonc.2022.03.011_bib149","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib150","first-page":"1","article-title":"RNA transcription and splicing errors as a source of cancer frameshift neoantigens for vaccines","volume":"9","author":"Shen","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-020-02240-8","article-title":"Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer","volume":"22","author":"Oka","year":"2021","journal-title":"Genome Biol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2022.03.011_bib152","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood-2019-131277","article-title":"Pipeline for discovering neoepitopes generated by alternative splicing in B-ALL","volume":"134","author":"Zheng","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.annonc.2022.03.011_bib153","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jcyt.2019.06.009","article-title":"Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy","volume":"21","author":"Blaeschke","year":"2019","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib154","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1038\/s41467-021-26936-y","article-title":"Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors","volume":"12","author":"Rivero-Hinojosa","year":"2021","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.annonc.2022.03.011_bib155","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.annonc.2022.03.011_bib156","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2022.03.011_bib157","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2022.03.011_bib158","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.leukres.2016.08.006","article-title":"Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL135INS","volume":"49","author":"Berman","year":"2016","journal-title":"Leuk Res"},{"issue":"24","key":"10.1016\/j.annonc.2022.03.011_bib159","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib160","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/s41598-019-38672-x","article-title":"Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients","volume":"9","author":"Chandrasekhar","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.annonc.2022.03.011_bib161","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/cancers10110458","article-title":"Aberrant RNA splicing in cancer and drug resistance","volume":"10","author":"Wang","year":"2018","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.annonc.2022.03.011_bib162","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1535-7163.MCT-08-0482","article-title":"BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations","volume":"7","author":"Lee","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib163","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A\u00a0common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Ng","year":"2012","journal-title":"Nat Med"},{"issue":"44","key":"10.1016\/j.annonc.2022.03.011_bib164","doi-asserted-by":"crossref","first-page":"77567","DOI":"10.18632\/oncotarget.20658","article-title":"Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.annonc.2022.03.011_bib165","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/ijc.30574","article-title":"Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action","volume":"140","author":"Smith","year":"2017","journal-title":"Int J Cancer"},{"issue":"S1","key":"10.1016\/j.annonc.2022.03.011_bib166","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.annonc.2022.03.011_bib167","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2022.03.011_bib168","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib169","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/cancers12030723","article-title":"Glucocorticoid resistant pediatric acute lymphoblastic leukemia samples display altered splicing profile and vulnerability to spliceosome modulation","volume":"12","author":"Sciarrillo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40265-018-0868-8","article-title":"Overview of current drugs and molecules in development for spinal muscular atrophy therapy","volume":"78","author":"Shorrock","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib171","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1086\/498853","article-title":"Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2","volume":"78","author":"Cartegni","year":"2006","journal-title":"Am J Hum Gent"},{"issue":"R2","key":"10.1016\/j.annonc.2022.03.011_bib172","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1093\/hmg\/ddx215","article-title":"Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape","volume":"26","author":"Wood","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"15","key":"10.1016\/j.annonc.2022.03.011_bib173","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1101\/gad.1961710","article-title":"Antisense oligonucleotides and spinal muscular atrophy: skipping along","volume":"24","author":"Burghes","year":"2010","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/s13380-013-0109-2","article-title":"Antisense oligonucleotide mediated therapy of spinal muscular atrophy","volume":"4","author":"Sivanesan","year":"2013","journal-title":"Transl Neurosci"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.annonc.2022.03.011_bib176","series-title":"FDA Approves Sarepta Therapeutics\u2019 Amondys 45 for Treatment of DMD Amenable to Skipping Exon 45.","author":"Gurunathan","year":"2021"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib177","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib178","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib179","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2022.03.011_bib180","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ymthe.2020.11.008","article-title":"Pharmacokinetics and proceedings in clinical application of nucleic acid therapeutics","volume":"29","author":"Herkt","year":"2021","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib181","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"7","key":"10.1016\/j.annonc.2022.03.011_bib182","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.tips.2021.04.010","article-title":"Overcoming the challenges of tissue delivery for oligonucleotide therapeutics","volume":"42","author":"G\u00f6kirmak","year":"2021","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.annonc.2022.03.011_bib183","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib184","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/molecules22050782","article-title":"Mesoporous silica nanoparticles as carriers for intracellular delivery of nucleic acids and subsequent therapeutic applications","volume":"22","author":"Cha","year":"2017","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/nat.2013.0450","article-title":"Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy","volume":"24","author":"Falzarano","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.annonc.2022.03.011_bib186","doi-asserted-by":"crossref","first-page":"1287128","DOI":"10.1155\/2016\/1287128","article-title":"A\u00a0polyethylenimine-containing and transferrin-conjugated lipid nanoparticle system for antisense oligonucleotide delivery to AML","volume":"2016","author":"Yuan","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.annonc.2022.03.011_bib187","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","volume":"240","author":"Santiago-Ortiz","year":"2016","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.annonc.2022.03.011_bib188","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.omtm.2020.04.025","article-title":"Long-term efficacy of AAV9-U7snRNA-mediated exon 51 skipping in mdx52 Mice","volume":"17","author":"Aupy","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"10.1016\/j.annonc.2022.03.011_bib189","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A\u00a0new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol Ther"},{"issue":"5702","key":"10.1016\/j.annonc.2022.03.011_bib190","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.annonc.2022.03.011_bib191","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","article-title":"Roles and mechanisms of alternative splicing in cancer\u2014implications for care","volume":"17","author":"Bonnal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2022.03.011_bib192","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molmed.2015.11.005","article-title":"Small molecule modulators of pre-mRNA splicing in cancer therapy","volume":"22","author":"Salton","year":"2016","journal-title":"Trends Mol Med"},{"issue":"18","key":"10.1016\/j.annonc.2022.03.011_bib193","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2017-02-692715","article-title":"How do messenger RNA splicing alterations drive myelodysplasia?","volume":"129","author":"Joshi","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib194","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.annonc.2022.03.011_bib195","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2022.03.011_bib196","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1261\/rna.056101.116","article-title":"Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators","volume":"22","author":"Qiu","year":"2016","journal-title":"RNA"},{"issue":"7367","key":"10.1016\/j.annonc.2022.03.011_bib197","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2022.03.011_bib198","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1381","article-title":"Modulating splicing with small molecular inhibitors of the spliceosome","volume":"8","author":"Effenberger","year":"2017","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"5","key":"10.1016\/j.annonc.2022.03.011_bib199","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233672","article-title":"An exon skipping screen identifies antitumor drugs that are potent modulators of pre-mRNA splicing, suggesting new therapeutic applications","volume":"15","author":"Shi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2022.03.011_bib200","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-94-017-9211-0_14","article-title":"Splice variants of MDM2 in oncogenesis","volume":"85","author":"Rosso","year":"2014","journal-title":"Subcell Biochem"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib201","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/1097-0215(20010520)95:3<168::AID-IJC1029>3.0.CO;2-A","article-title":"Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma","volume":"95","author":"Bartel","year":"2001","journal-title":"Int J Cancer"},{"issue":"11-12","key":"10.1016\/j.annonc.2022.03.011_bib202","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3727\/096504001108747459","article-title":"Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines","volume":"12","author":"Bartel","year":"2001","journal-title":"Oncol Res"},{"issue":"3","key":"10.1016\/j.annonc.2022.03.011_bib203","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ijc.20073","article-title":"Limited relevance of the CHEK2 gene in hereditary breast cancer","volume":"110","author":"Dufault","year":"2004","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2022.03.011_bib204","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006360","article-title":"ggsashimi: Sashimi plot revised for browser-and annotation-independent splicing visualization","volume":"14","author":"Garrido-Mart\u00edn","year":"2018","journal-title":"PLoS Comput Biol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422003908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422003908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:15:32Z","timestamp":1778548532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753422003908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":204,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0923753422003908"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.03.011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}